Repository logo
 

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England.

Accepted version
Peer-reviewed

No Thumbnail Available

Type

Article

Change log

Authors

Chand, Meera 
Barrett, Jeffrey C 
Johnson, Robert 

Abstract

The SARS-CoV-2 lineage B.1.1.7, designated variant of concern (VOC) 202012/01 by Public Health England1, was first identified in the UK in late summer to early autumn 20202. Whole-genome SARS-CoV-2 sequence data collected from community-based diagnostic testing for COVID-19 show an extremely rapid expansion of the B.1.1.7 lineage during autumn 2020, suggesting that it has a selective advantage. Here we show that changes in VOC frequency inferred from genetic data correspond closely to changes inferred by S gene target failures (SGTF) in community-based diagnostic PCR testing. Analysis of trends in SGTF and non-SGTF case numbers in local areas across England shows that B.1.1.7 has higher transmissibility than non-VOC lineages, even if it has a different latent period or generation time. The SGTF data indicate a transient shift in the age composition of reported cases, with cases of B.1.1.7 including a larger share of under 20-year-olds than non-VOC cases. We estimated time-varying reproduction numbers for B.1.1.7 and co-circulating lineages using SGTF and genomic data. The best-supported models did not indicate a substantial difference in VOC transmissibility among different age groups, but all analyses agreed that B.1.1.7 has a substantial transmission advantage over other lineages, with a 50% to 100% higher reproduction number.

Description

Keywords

Adolescent, Adult, Age Distribution, Aged, Aged, 80 and over, Basic Reproduction Number, COVID-19, Child, Child, Preschool, England, Evolution, Molecular, Genome, Viral, Humans, Infant, Infant, Newborn, Middle Aged, Phylogeny, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Time Factors, Young Adult

Journal Title

Nature

Conference Name

Journal ISSN

0028-0836
1476-4687

Volume Title

593

Publisher

Springer Science and Business Media LLC

Rights

All rights reserved
Sponsorship
MRC (MC_PC_19027)
UK Research and Innovation (MC_PC_19027)
COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the UK National Institute for Health Research (NIHR), and Genome Research (operating as the Wellcome Sanger Institute).